<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32951651</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>22</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>22</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-5150</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>111</Volume>
            <PubDate>
              <Year>2020</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Pediatric neurology</Title>
          <ISOAbbreviation>Pediatr Neurol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Zonisamide Therapy for Patients With Paroxysmal Kinesigenic Dyskinesia.</ArticleTitle>
        <Pagination>
          <StartPage>23</StartPage>
          <EndPage>26</EndPage>
          <MedlinePgn>23-26</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pediatrneurol.2020.06.017</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0887-8994(20)30225-3</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">We evaluated zonisamide therapy in patients with paroxysmal kinesigenic dyskinesia (PKD).</AbstractText>
          <AbstractText Label="METHODS">We analyzed zonisamide therapy in 17 patients with PKD at Saitama Children's Medical Center between November 1994 and April 2020. We collected information regarding family history, previous history, age at onset, age at zonisamide commencement, dyskinesia characteristics, brain magnetic resonance imaging, interictal electroencephalography, treatment lag, zonisamide efficacy, zonisamide dose, serum zonisamide concentration, and adverse effects. We evaluated PKD frequency at six months after zonisamide therapy commencement.</AbstractText>
          <AbstractText Label="RESULTS">Fourteen patients met the inclusion criteria. The median age at zonisamide therapy commencement was 12.8 (9.4 to 16.3) years. Zonisamide therapy was effective in 13 of 14 (92.9%) patients: complete remission for more than three months after zonisamide therapy (n = 7), decreased dyskinesia frequency by more than 90% (n = 4), dyskinesia frequency by 75% to 90% (n = 2), and no change of dyskinesia frequency (n = 1). The initial and maintenance zonisamide doses were 2.0 (1.4 to 3.8) and 2.0 (1.5 to 5.9) mg/kg/day, respectively. The median duration between zonisamide therapy commencement and dyskinesia decrease or cessation was 4 (1 to 60) days: 10 of 14 (71.4%) patients responded to zonisamide within one week after zonisamide therapy commencement. Regarding adverse effects, two patients experienced somnolence and one developed reduced perspiration.</AbstractText>
          <AbstractText Label="CONCLUSIONS">We suggest that zonisamide monotherapy is effective for patients with PKD as a first-line treatment. We can evaluate the efficacy of zonisamide therapy within one week. Because zonisamide lacks the enzyme-inducing effects of carbamazepine and phenytoin, it may be useful for PKD treatment.</AbstractText>
          <CopyrightInformation>Copyright © 2020 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Matsuura</LastName>
            <ForeName>Ryuki</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Neurology, Saitama Children's Medical Center, Saitama, Japan; Department of Pediatrics, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan. Electronic address: ryuki@jikei.ac.jp.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hamano</LastName>
            <ForeName>Shin-Ichiro</ForeName>
            <Initials>SI</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Neurology, Saitama Children's Medical Center, Saitama, Japan; Division of Child Health and Human Development, Saitama Children's Medical Center, Saitama, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hiwatari</LastName>
            <ForeName>Erika</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ikemoto</LastName>
            <ForeName>Satoru</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hirata</LastName>
            <ForeName>Yuko</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Neurology, Saitama Children's Medical Center, Saitama, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Koichihara</LastName>
            <ForeName>Reiko</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Child Health and Human Development, Saitama Children's Medical Center, Saitama, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kikuchi</LastName>
            <ForeName>Kenjiro</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Child Health and Human Development, Saitama Children's Medical Center, Saitama, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>06</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Pediatr Neurol</MedlineTA>
        <NlmUniqueID>8508183</NlmUniqueID>
        <ISSNLinking>0887-8994</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>459384H98V</RegistryNumber>
          <NameOfSubstance UI="D000078305">Zonisamide</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <SupplMeshList>
        <SupplMeshName Type="Disease" UI="C537180">Familial paroxysmal dystonia</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004421" MajorTopicYN="N">Dystonia</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017063" MajorTopicYN="Y">Outcome Assessment, Health Care</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012074" MajorTopicYN="N">Remission Induction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000078305" MajorTopicYN="N">Zonisamide</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Adverse effects</Keyword>
        <Keyword MajorTopicYN="Y">Antiepileptic drugs</Keyword>
        <Keyword MajorTopicYN="Y">Children</Keyword>
        <Keyword MajorTopicYN="Y">Choreoathetosis</Keyword>
        <Keyword MajorTopicYN="Y">Dystonia</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>21</Day>
          <Hour>5</Hour>
          <Minute>32</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32951651</ArticleId>
        <ArticleId IdType="doi">10.1016/j.pediatrneurol.2020.06.017</ArticleId>
        <ArticleId IdType="pii">S0887-8994(20)30225-3</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
